Barclays
ANTX icon

Barclays’s AN2 Therapeutics ANTX Stock Holding History

Barclays’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.6K Buy
5,491
+5,091
+1,273% +$21.9K ﹤0.01% 4524
2026
Q1 		$1.37K Buy
+400
New +$826 ﹤0.01% 4886
2024
Q2 		– Sell
-28,318
Closed -$92K – 4845
2024
Q1 		$92K Sell
28,318
-15,920
-36% -$173K ﹤0.01% 4461
2023
Q4 		$906K Buy
44,238
+41,068
+1,296% +$687K ﹤0.01% 3508
2023
Q3 		$51K Sell
3,170
-23,904
-88% -$271K ﹤0.01% 3860
2023
Q2 		$230K Sell
27,074
-5,699
-17% -$41K ﹤0.01% 3177
2023
Q1 		$323K Buy
32,773
+2,715
+9% +$30.2K ﹤0.01% 3536
2022
Q4 		$286K Buy
30,058
+2,780
+10% +$37.2K ﹤0.01% 3653
2022
Q3 		$475K Buy
27,278
+22,390
+458% +$261K ﹤0.01% 2734
2022
Q2 		$38K Sell
4,888
-13,332
-73% -$177K ﹤0.01% 4145
2022
Q1 		$275K Buy
+18,220
New +$276K ﹤0.01% 3241

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Barclays's ANTX Position: Q2 2026 in Review

Barclays increased its AN2 Therapeutics (ANTX) stake by 1,273% in Q2 2026, buying an estimated $21.9K and bringing the position to 5,491 shares worth $26.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4524.

Barclays first reported a position in ANTX in Q1 2022 and has held it in 11 quarters since. The position peaked at $906K in Q4 2023. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Barclays held 5,491 shares of AN2 Therapeutics worth $26.6K as of Q2 2026.
  • Barclays bought 5,091 AN2 Therapeutics shares in Q2 2026, an estimated $21.9K.
  • AN2 Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4524 holding.
  • Barclays first reported a position in AN2 Therapeutics in Q1 2022 and has held it in 11 quarters since.
  • Barclays's AN2 Therapeutics position peaked at $906K in Q4 2023.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.